
    
      Secondary Objective(s):

        1. Describe persistence of ALT (alanine aminotransferase) normalization and/or improvement
           of ALT levels with TAF as with previous anti-HBV treatment

        2. To describe trends in serum creatinine and calculated creatinine clearance as available
           by local labs.

        3. To describe trends in bone mass from baseline to 24 months after switch.
    
  